Euracan

Euracan EURACAN is the European Refrence Network (ERN) for rare adult solid cancers: 1 of the 24 ERNs working on a range of thematic issues.

EURACAN connects patients who have rare adult solid cancers to expert health care centres across Europe
We aim to tackle these complex and rare cancers that require highly specialised treatment and concentrated knowledge and resources. Patients: https://euracan.eu/patients/how-euracan-helps-you/
Health professionals: https://euracan.eu/health-professionals/how-euracan-helps-health-professionals/

From 12–14 March 2026, the international sarcoma and rare cancercommunity gathered in Lugano for the Sarcoma and Rare C...
13/04/2026

From 12–14 March 2026, the international sarcoma and rare cancercommunity gathered in Lugano for the Sarcoma and Rare CancersCongress 2026, one of the leading scientific meetings dedicated to theseoften under-represented tumour types.

The collaboration between EURACAN and ESMO continues to play a key role instrengthening the European ecosystem for rare cancer care and research. Thecongress provides a valuable platform for EURACAN clinicians and researchers toengage with the broader oncology community and exchange expertise withcolleagues from across Europe and beyond.

Events such as the ESMO Sarcoma and Rare Cancers Congress underline theimportance of collaboration across networks, institutions, and disciplines. ForEURACAN, participation in this congress reinforces its mission to strengthencooperation among specialised centres, accelerate research progress, andsupport the development of evidence-based guidelines for rare cancers.

📢 Call to Action for the rare cancer & rare disease communityWe invite all ERN members to endorse and sign the Declarati...
13/02/2026

📢 Call to Action for the rare cancer & rare disease community

We invite all ERN members to endorse and sign the Declaration on a European Innovation and Care Ecosystem for Rare and Complex Diseases, launched during the High Level Meeting for Rare and Complex Diseases (HLM Rare) in December 2025.

This joint political and strategic commitment — developed with patients, healthcare professionals, ERNs, academia and industry — sets out 8 Priority Actions to accelerate progress, improve access to diagnosis and treatment, strengthen clinical research and infrastructure, and secure sustainable funding for ERNs in the 2028–2034 EU framework.

By signing, you help:
• Drive a comprehensive EU Action Plan on Rare Diseases
• Strengthen recognition and long-term sustainability of ERNs
• Amplify our collective voice in EU policy and funding priorities
‍
Over 50 organisations have already joined — now it’s our turn to make an impact.
Sign the Declaration via the link in bio and indicate your ERN affiliation (or “not applicable”).

Thank you for your continued commitment to advancing care for people living with rare and complex diseases.

Season’s Greetings from EURACAN ✨As the year comes to a close, we would like to thank all our members, partners, healthc...
23/12/2025

Season’s Greetings from EURACAN ✨

As the year comes to a close, we would like to thank all our members, partners, healthcare professionals, patient representatives, and collaborators for their engagement and commitment to improving care for patients with rare adult solid cancers across Europe.
We wish you a Merry Christmas and a joyful holiday season, and we look forward to continuing our collaboration in the year ahead.

Warm regards,
The EURACAN Coordination Team

The European Commission has published the first-ever Continuous Monitoring Report for the ERNs, confirming a 160% increa...
01/12/2025

The European Commission has published the first-ever Continuous Monitoring Report for the ERNs, confirming a 160% increase in new patients referred to ERN centres between 2018 and 2024 — clear evidence of how this EU infrastructure strengthens Europe’s health capacity and resilience. The report presents detailed indicators across seven core areas, including clinical activity, guidelines, registries, training and cross-border collaboration, reflecting the 2023 & 2024 monitoring cycles.

ERNs connect 1,600+ specialised units in 375 hospitals, creating a single pool of rare disease expertise no country could build alone. An estimated 30 million EU citizens are living with a rare disease. That's a huge challenge, and ERNs are working together to make sure everyone gets the specialised care they need.

The report documents over 2,100 virtual CPMS consultations, delivering expert, multidisciplinary advice across borders so patients can access specialist input without the need to travel.

ERNs, demonstrate the power of European cooperation — strengthening health resilience, supporting clinical excellence, and improving access to expertise for rare disease patients across all Member States.

Read the report and learn more about how ERNs — and the clinicians and multidisciplinary teams who power them — support patients across Europe.

Link in bio

Last week, EURACAN held a high-level brainstorming session that brought together leading European experts to exchange id...
03/11/2025

Last week, EURACAN held a high-level brainstorming session that brought together leading European experts to exchange ideas and define strategic directions for advancing care and research in rare cancers.

The meeting fostered in-depth discussions across several priority areas:

-Artificial Intelligence (AI): exploring its role in improving diagnosis, decision support, and research integration.
- Clinical and Translational Research: bridging innovation with patient care to accelerate the development of effective therapies.
- Data Research: enhancing data sharing, quality, and interoperability to strengthen evidence generation.
- Development of Guidelines – Expert vs. Evidence: examining the balance between expert consensus and data-driven recommendations.
- Funding Opportunities, Partnerships, and Policies: identifying mechanisms to support sustainable collaboration across Europe.
- Rare Cancer Forum: reinforcing exchange and multi-stakeholder engagement.

The session underscored EURACAN’s commitment to fostering collaboration and innovation in the field of rare cancers. By bringing together multidisciplinary expertise from across Europe, EURACAN continues to strengthen the collective effort to improve outcomes for patients with rare cancers.

Adres

Amsterdam

Website

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Euracan nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Snelkoppelingen

Uitgelicht

Delen

Type